

## Product Specification Sheet

**Product Name:** NVP-AUY922

**Catalog Number:** C6278

**Technical information:**

Chemical Formula:  $C_{26}H_{31}N_3O_5$

CAS #: 747412-49-3

Molecular Weight: 465.54

Purity: > 99%


Appearance: White solid

Solubility: Soluble in DMSO up to 100 mM

Chemical Name: 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide

Storage: Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



- Handling:**
- To make 10 mM stock solution, add 0.215mL of DMSO for each mg of NVP-AUY922
  - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

**Biological Activity:** NVP-AUY922 is a resorcinol-based, intravenous or intraperitoneal Phase II clinical trial HSP90 inhibitor with a  $K_d$  of 1.7 nM. It inhibits tumor cell proliferation at GI50 values of 2-40 nM, inducing G1-G2 arrest and apoptosis. [1] Daily dosing of NVP-AUY922 (50 mg/kg, iv or ip) produced statistically significant tumor inhibition or regression (treated/control) in BT474 breast, 21%; A2780 ovarian, 11%; U87MG glioblastoma, 7%; PC3 prostate, 37%; and WM266.4 melanoma, 31%. [1]

Pharmacodynamically, NVP-AUY922 induces HSP70 and depletes ERBB2, CRAF, CDK4, phospho-AKT/TotalAKT, and HIF-1a.

**Reference:** 1. Eccles et al., NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. *Cancer Res.* 2008, 68, 2850-2860. Pubmed ID: 18413753

To reorder: <http://www.cellagentech.com/NVP-AUY922/>

For Technical Support: [technical@cellagentech.com](mailto:technical@cellagentech.com)

*Chemicals are sold for research use only, not for clinical or diagnostic use.*